188 related articles for article (PubMed ID: 16298073)
1. The emerging role of DNA repair proteins as predictive, prognostic and therapeutic targets in cancer.
Madhusudan S; Middleton MR
Cancer Treat Rev; 2005 Dec; 31(8):603-17. PubMed ID: 16298073
[TBL] [Abstract][Full Text] [Related]
2. PARP inhibitors for cancer therapy.
Curtin NJ
Expert Rev Mol Med; 2005 Mar; 7(4):1-20. PubMed ID: 15836799
[TBL] [Abstract][Full Text] [Related]
3. PARP inhibitors--current status and the walk towards early breast cancer.
Glendenning J; Tutt A
Breast; 2011 Oct; 20 Suppl 3():S12-9. PubMed ID: 22015278
[TBL] [Abstract][Full Text] [Related]
4. Emerging cancer therapeutic opportunities target DNA-repair systems.
Ding J; Miao ZH; Meng LH; Geng MY
Trends Pharmacol Sci; 2006 Jun; 27(6):338-44. PubMed ID: 16697054
[TBL] [Abstract][Full Text] [Related]
5. [Dbait: An innovative concept to inhibit DNA repair and treat cancer].
Biau J; Devun F; Verrelle P; Dutreix M
Bull Cancer; 2016 Mar; 103(3):227-35. PubMed ID: 26917468
[TBL] [Abstract][Full Text] [Related]
6. Putting poly (ADP-ribose) polymerase and other DNA repair inhibitors into clinical practice.
Helleday T
Curr Opin Oncol; 2013 Nov; 25(6):609-14. PubMed ID: 24097104
[TBL] [Abstract][Full Text] [Related]
7. The role of DNA repair pathways in cisplatin resistant lung cancer.
O'Grady S; Finn SP; Cuffe S; Richard DJ; O'Byrne KJ; Barr MP
Cancer Treat Rev; 2014 Dec; 40(10):1161-70. PubMed ID: 25458603
[TBL] [Abstract][Full Text] [Related]
8. [PARP inhibitors: significant progress in cancer therapy].
Dantzer F; Noel G; Schreiber V
Bull Cancer; 2011 Mar; 98(3):277-90. PubMed ID: 21459712
[TBL] [Abstract][Full Text] [Related]
9. High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs.
Rottenberg S; Jaspers JE; Kersbergen A; van der Burg E; Nygren AO; Zander SA; Derksen PW; de Bruin M; Zevenhoven J; Lau A; Boulter R; Cranston A; O'Connor MJ; Martin NM; Borst P; Jonkers J
Proc Natl Acad Sci U S A; 2008 Nov; 105(44):17079-84. PubMed ID: 18971340
[TBL] [Abstract][Full Text] [Related]
10. Poly(ADP-ribose) polymerase inhibitors in cancer treatment: a clinical perspective.
Sandhu SK; Yap TA; de Bono JS
Eur J Cancer; 2010 Jan; 46(1):9-20. PubMed ID: 19926276
[TBL] [Abstract][Full Text] [Related]
11. Poly(ADP-ribose)polymerase (PARP) inhibitors: from bench to bedside.
Plummer R
Clin Oncol (R Coll Radiol); 2014 May; 26(5):250-6. PubMed ID: 24602564
[TBL] [Abstract][Full Text] [Related]
12. DNA repair inhibition: a selective tumour targeting strategy.
Madhusudan S; Hickson ID
Trends Mol Med; 2005 Nov; 11(11):503-11. PubMed ID: 16214418
[TBL] [Abstract][Full Text] [Related]
13. Current development of clinical inhibitors of poly(ADP-ribose) polymerase in oncology.
Ratnam K; Low JA
Clin Cancer Res; 2007 Mar; 13(5):1383-8. PubMed ID: 17332279
[TBL] [Abstract][Full Text] [Related]
14. Poly(ADP-ribose) polymerase-1 protects excessive DNA strand breaks from deterioration during repair in human cell extracts.
Parsons JL; Dianova II; Allinson SL; Dianov GL
FEBS J; 2005 Apr; 272(8):2012-21. PubMed ID: 15819892
[TBL] [Abstract][Full Text] [Related]
15. Biomarkers of Response and Resistance to DNA Repair Targeted Therapies.
Stover EH; Konstantinopoulos PA; Matulonis UA; Swisher EM
Clin Cancer Res; 2016 Dec; 22(23):5651-5660. PubMed ID: 27678458
[TBL] [Abstract][Full Text] [Related]
16. [On the prospects of using the DNA repair inhibitors in radiotherapy of tumors].
Gaziev AI
Radiats Biol Radioecol; 2014; 54(3):229-40. PubMed ID: 25764827
[TBL] [Abstract][Full Text] [Related]
17. Poly(ADP-ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinic.
Yap TA; Sandhu SK; Carden CP; de Bono JS
CA Cancer J Clin; 2011; 61(1):31-49. PubMed ID: 21205831
[TBL] [Abstract][Full Text] [Related]
18. The novel poly(ADP-Ribose) polymerase inhibitor, AG14361, sensitizes cells to topoisomerase I poisons by increasing the persistence of DNA strand breaks.
Smith LM; Willmore E; Austin CA; Curtin NJ
Clin Cancer Res; 2005 Dec; 11(23):8449-57. PubMed ID: 16322308
[TBL] [Abstract][Full Text] [Related]
19. PARP-1 and Ku compete for repair of DNA double strand breaks by distinct NHEJ pathways.
Wang M; Wu W; Wu W; Rosidi B; Zhang L; Wang H; Iliakis G
Nucleic Acids Res; 2006; 34(21):6170-82. PubMed ID: 17088286
[TBL] [Abstract][Full Text] [Related]
20. Coordination of DNA mismatch repair and base excision repair processing of chemotherapy and radiation damage for targeting resistant cancers.
Kinsella TJ
Clin Cancer Res; 2009 Mar; 15(6):1853-9. PubMed ID: 19240165
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
